Trial Profile
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tocilizumab (Primary)
- Indications Cancer metastases; Malignant melanoma
- Focus Therapeutic Use
- 24 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jul 2023.
- 24 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2022 Planned End Date changed from 1 Jun 2024 to 1 Nov 2024.